Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk
复制标题
DOI：
10.1016/j.amjcard.2008.02.039
复制
发表时间：
2008-04-17
影响因子：
2.8
通讯作者：
Zhao, Xue-Qiao
中科院分区：
文献类型：
--
作者：
Brown, B. Greg;Zhao, Xue-Qiao
目前的高风险脂质紊乱治疗指南没有规定高密度脂蛋白（HDL）胆固醇的治疗目标水平，用于预防高风险人群的心血管疾病。然而，正如本报告所述，基础科学和流行病学研究以及临床试验提供了大量证据，这些证据提供了强有力的一致信息，即通过治疗手段提高HDL胆固醇将有效降低心血管风险，而不依赖于低密度脂蛋白（LDL）胆固醇的降低。治疗性HDL胆固醇升高，最有效地实现烟酸（烟酸），似乎至少是有效的可比百分比的LDL胆固醇降低动脉粥样硬化进展或临床心血管事件的减少，在广泛的风险水平。这一策略的广泛采用还需要等待正在进行的高密度脂蛋白胆固醇升高的大型对照临床试验的结果。(C)2008年爱思唯尔公司All rights reserved.
The current guidelines for the treatment of high risk lipid disorders do not specify a therapeutic target level of high-density lipoprotein (HDL) cholesterol for cardiovascular disease prevention in high-risk populations. However, as described in this report, there is a substantial body of evidence from basic science and epidemiologic studies and from clinical trials providing the strong, consistent message that raising HDL cholesterol by therapeutic means will effectively reduce cardiovascular risk independently of reductions in low-density lipoprotein (LDL) cholesterol. Therapeutic HDL cholesterol raising, most effectively achieved by nicotinic acid (niacin), appears to be at least as effective as comparable percentages of LDL cholesterol lowering for the reduction of atherosclerosis progression or clinical cardiovascular events, over a broad range of risk levels. The widespread adoption of this strategy awaits the results of large, ongoing controlled clinical trials of HDL cholesterol raising. (C) 2008 Elsevier Inc. All rights reserved.